Five Prime Therapeutics Inc (FPRX.OQ)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|67||2018||Executive Chairman of the Board|
|47||2018||President, Chief Executive Officer, Chief Operating Officer, Director|
|61||2013||Chief Financial Officer, Senior Vice President|
|56||2016||Senior Vice President, Development Sciences|
|54||2017||Senior Vice President and Chief Medical Officer|
- BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb
- BRIEF-Five Prime Announces Pricing Of Upsized Public Offering Of Common Stock
- BRIEF-Five Prime Announces Proposed Public Offering Of Common Stock
- BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb
- BRIEF-Five Prime Therapeutics Submits Investigational New Drug Application For FPA150